Monitoring vocal biomarkers is an exceptionally effective tool for early detection and ongoing assessment of conditions such as Alzheimer's, Parkinson's, Dementia, PTSD, and Huntington's Disease. This technique is also crucial for evaluating fatigue and energy levels, especially in operators of commercial trucks, cars, and heavy machinery. Looking ahead, we plan to enhance our models to also identify and analyze changes in anxiety, stress, and mood.
AxonDAO’s cutting-edge computational platform, originally designed to develop sophisticated machine learning models, now supports our innovative approach to voice data analysis. By integrating this technology with standardized questionnaires and deterministic chaos models, we have significantly enriched our analytical capabilities. This fusion of data not only builds on our previous psychoprofiling research but also underscores our commitment to utilizing advanced technology for precise and comprehensive analysis.
Risk management and compliance, when approached strategically, have the potential to go beyond mitigating threats.
By employing AI-driven voice analysis, we are able to detect early signs of adverse health conditions.
Predictive AI capabilities enable swift action, allowing individuals to address potential health issues well in advance.
Utilizing blockchain technology, we ensure that voice data remains secure, unalterable, and fully traceable. This empowers patients with complete ownership and control over their data, allowing them to decide who can access it for research purposes.
Providing users with full control over their data enhances trust and promotes sustained engagement with decentralized science projects.
On average, individuals diagnosed with Alzheimer's disease have a life expectancy ranging from three to 11 years, although some may live beyond 20 years. The level of impairment at the time of diagnosis significantly influences survival times.
For those affected by Huntington's disease, the progression is gradual but inevitable, with life expectancy generally ranging from 10 to 30 years after diagnosis. In contrast, juvenile Huntington's disease typically results in death within 10 years of symptom onset.
Meta-analyses indicate that PTSD is associated with a 47% increase in mortality risk, according to six studies that reported odds ratios (OR) or relative risks (RR), and a 32% increase in mortality risk in 18 studies that focused on the time until death, compared to individuals without PTSD.
The breadth of research goes beyond the primary focus of VitaDAO. Notably, it is documented that every dollar invested in prevention saves at least four times that amount in future treatment costs.
Double Anonymization Mechanism:
Adheres to HIPAA standards with an added layer of zero-knowledge anonymization.
Data Collection Module:
Captures audio and other relevant patient data vectors.
Analytical Engine:
Utilizes ML-based deterministic chaos models to generate a biomarker data grid as a pioneering solution.
User Access:
Empowers users with control over their data, including who can access it and under what conditions (e.g., medical personnel, researchers).
Privacy:
Leverages blockchain transparency, enabling users to monitor the usage of their data, thereby enhancing trust.
Positive Feedback:
Incentivizes patient participation by rewarding them with tokens for their data contributions.
Anonymized Data Brokerage:
Permits third-party analytics exclusively on data stored within the project's secure vault.
Analytical Project Creation:
Facilitates the development of analytical projects using the dataset through AxonDAO.
Compliance:
Fully compliant with HIPAA and GDPR regulations.
Sheridan, WY 82801 USA
© 2024 AxonDAO LLC EIN 92-1057519
